Meteen naar de inhoud

Hydrogen Water reduce Brain Damage

Hydrogen Water reduce Brain Damage from Hypoxic-ischemic encephalopathy

Hypoxic-ischemic encephalopathy (HIE) is a devastating condition, especially in newborns, that arises from a lack of oxygen to the brain.

It can lead to lifelong neurological problems and even death. In this two-part series, we explore an innovative treatment approach using hydrogen water to combat HIE and its impact on specific biomarkers: neuron-specific enolase (NSE), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α).

hypoxic-ischemic encephalopathy


HIE is a significant concern worldwide, particularly in developing countries. It results from perinatal asphyxia, causing brain damage due to reduced or suspended blood flow to the brain. Inflammation plays a crucial role in the development of HIE, triggering a cascade of harmful effects in nerve cells. Elevated levels of IL-6, TNF-α, and NSE in the blood are indicative of the severity of HIE.

Current Treatment Challenges:

While various treatments for HIE have been explored, comprehensive therapy is often recommended. However, these treatments can be expensive, controversial, or have limited effectiveness. Identifying a cost-effective, targeted treatment is essential for improving outcomes in newborns with HIE.

Hydrogen Water as a Potential Solution for Hypoxic-ischemic Encephalopathy

Hydrogen water, enriched with hydrogen ions, has shown promise as a therapeutic agent due to its potent antioxidant properties. It can effectively neutralize harmful reactive oxygen species (free radicals) in the body without side effects. Previous studies have demonstrated its efficacy in conditions like senile dementia, cardiovascular diseases, and arteriosclerosis. Our Study: Since 2014, hydrogen water has been utilized in the treatment of HIE at the Affiliated Hospital of Taishan Medical University with positive outcomes. Our study retrospectively analyzed its therapeutic effects on neonatal HIE and its protective mechanisms by measuring serum NSE, IL-6, and TNF-α levels before and after treatment.

Results and Conclusion

Our analysis revealed that the hydrogen water group exhibited significantly lower efficacy indicators compared to the conventional group. Serum NSE, IL-6, and TNF-α levels, which were elevated in HIE patients before treatment, decreased notably after hydrogen water therapy. This suggests that hydrogen water may play a protective role in reducing these biomarkers and potentially improving outcomes in HIE newborns. HIE is a significant health concern, particularly in developing countries like China. Our study suggests that hydrogen water could be a valuable addition to HIE treatment protocols, offering a cost-effective and safe option for reducing inflammation and improving outcomes for newborns. Further research is needed to explore its full potential in clinical settings.